While investigational studies of the VEGF-related factor levels remain promising, routine screening for clinical warning signs of PRES (hypertension, proteinuria, and hyperreflexia) may offer a practical surveillance strategy whereby discontinuing the offending agent and aggressively controlling BP may prevent PRES or PRES recurrence. This evidence concerns the gene VEGFA and Hyperreflexia.